The Society for Nuclear Medicine and Molecular Imaging (SNMMI) is challenging the Centers for Medicare & Medicaid Services (CMS) to expand coverage for Amyloid PET. CMS had previously issued a national coverage determination (NCD) analysis for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease. The letter with recommendations comes after continuous consultation with other stakeholders and response to requests for comment on the proposed decision. As of January 11, 2022, CMS had declared the therapy was to be covered. The decision would occur under coverage with evidence development (CED). SNNMI’s letter outlines several areas of opportunity for improvement when it comes to amyloid PET coverage.
With the current national coverage determination NCD 220.6.20, Medicare will only provide coverage for amyloid PET when it is administered in the setting of an approved clinical study under the Coverage with Evidence Development (CED) policy. According to SNNMI, “In the draft national coverage determination (NCD) on monoclonal antibodies, CMS proposes to provide the following coverage for amyloid PET:
For any CMS approved trials, or trials supported by the NIH, that include a beta amyloid positron emission tomography (PET) scan as part of the protocol, it has been determined that these trials also meet the CED requirements included in the Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease NCD (220.6.20), and one beta amyloid PET scan will be covered per patient, if the patient did not previously receive a beta amyloid PET scan.” The proposal is flawed because it incorrectly restricts access to the vital diagnostic data that is furnished by amyloid PET scans while creating “inefficiencies for study sponsors and patients.”
Another consequence is the potential for economic and emotional stress on patients who experience mild cognitive impairment and must devote time and resources to enrolling in a clinical trial prior to receiving a PET scan, “only to often find out after enrollment that they are not eligible to receive monoclonal antibodies because there is no beta-amyloid present in their brain.” Based on these flaws and more, the organization has advocated for a number of key improvements in a final NCD.
• Coverage existing prior to a patient deemed eligible for an approved study
The draft NCD dictates that amyloid PET coverage is restricted to the conditions where it is performed as part of the protocol for a study that adheres to CED requirements for coverage of monoclonal antibodies, essentially limiting coverage to patients enrolled in a clinical trial.
PET scans, they argue, provide critical information to assess whether the patient meets specific criteria, evaluating whether the patient actually has amyloid pathology that may align with Alzheimer’s disease (AD). The patient must be actively in the trial if study sponsors want to obtain data that assess if a patient is a candidate for therapy and ultimately a candidate for a clinical trial.
SNNMI notes that “This requirement is illogical, highly inefficient, and will create significant burdens for both trial sponsors and patients. Enrolling patients in a clinical trial, including obtaining the necessary informed consent agreement, requires substantial time and resources. It also requires educating the patient about the trial, the potential benefits of the study therapy, and the associated risks.”
The Amyloid PET allows the identification of any patients who will not receive benefit from aducanumab ahead of time while de-complicating the enrollment process for both patients and trial sponsors. The PET also makes patient care more efficient for those that don’t present with beta-amyloid since treating professionals and caregivers are free to concentrate on treatment methods that best match the patients’ needs.
Therefore, CMS should ultimately not restrict coverage purely to trial participants but must allow coverage of amyloid PET to ascertain whether the patient should be in the trial at all. According to SNMMI, “This will require that CMS finalize cover- age for one PET scan to all patients considered candidates for aducanumab. CMS could accomplish this by retiring the beta amyloid CED NCD or by establishing additional, non-CED coverage of beta amyloid PET as part of the monoclonal antibody NCD….we recommend that CMS retire NCD 220.6.20.”
With the letter providing strong reasoning for change, these are not all the arguments SNMMI has for coverage. Explore more regulatory, policy, and coding knowledge to master compliance and coding with our monthly Radiology Compliance Manager.
Information Sources:
http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=39886
MedLearn Media is launching an online resource believed to be useful for professional coders, charge capture, compliance, and revenue integrity specialists alike. DrugCode Pro is
I recently came across a denial indicating that a query was noncompliant because it did not include evidence why the query was needed. I was
Please log in to your account to comment on this article.
Stop revenue leakage and boost hospital performance by mastering risk adjustment and HCCs. This essential webcast with expert Cheryl Ericson, RN, MS, CCDS, CDIP, will reveal how inaccurate patient acuity documentation leads to lost reimbursements through penalties from poor quality scores. Learn the critical differences between HCCs and traditional CCs/MCCs, adapt your CDI workflows, and ensure accurate payments in Medicare Advantage and value-based care models. Perfect for HIM leaders, coders, and CDI professionals. Don’t miss this chance to protect your hospital’s revenue and reputation!
Struggling with ICD-10-CM coding for diabetes and complications? This expert-led webcast clarifies complex combination codes, documentation gaps, and sequencing rules to reduce denials and ensure compliance. Dr. Angela Comfort will provide actionable strategies to accurately link diabetes to complications, improve provider documentation, and optimize reimbursement—helping coders, CDI specialists, and HIM leaders minimize audit risks and strengthen revenue integrity. Don’t miss this chance to master diabetes coding with real-world case studies, key takeaways, and live Q&A!
Uncover critical guidance. HIM coding expert, Kay Piper, RHIA, CDIP, CCS, provides an interactive review on important information in each of the AHA’s 2025 ICD-10-CM/PCS Quarterly Coding Clinics in easy-to-access on-demand webcasts, available shortly after each official publication.
Uncover critical guidance. Kay Piper provides an interactive review on coding guidelines and more in the AHA’s fourth quarter 2025 ICD-10-CM/PCS Coding Clinic in an easy to access on-demand webcast.
Stay ahead of Medicare Advantage’s 2025-2026 regulatory changes in this critical webcast featuring expert Tiffany Ferguson, LMSW, CMAC, ACM. Learn how new CMS rules limit MA plan denials, protect hospitals from retroactive claim reopenings, and modify Two-Midnight Rule enforcement—plus key insights on omitted SDoH mandates and heightened readmission scrutiny. Discover actionable strategies to safeguard revenue, ensure compliance, and adapt to evolving health equity priorities before the June 2025 deadline. Essential for hospitals, revenue cycle teams, and compliance professionals navigating MA’s shifting landscape.
Struggling with CMS’s 3-Day Payment Window? Join compliance expert Michael G. Calahan, PA, MBA, CCO, to master billing restrictions for pre-admission and inter-facility services. Learn how to avoid audit risks, optimize revenue cycle workflows, and ensure compliance across departments. Critical for C-suite leaders, providers, coders, revenue cycle teams, and compliance teams—this webcast delivers actionable strategies to protect reimbursements and meet federal regulations.
Providers face increasing Medicare audits when using skin substitute grafts, leaving many unprepared for claim denials and financial liabilities. Join veteran healthcare attorney Andrew B. Wachler, Esq., in this essential webcast and master the Medicare audit process, learn best practices for compliant billing and documentation, and mitigate fraud and abuse risks. With actionable insights and a live Q&A session, you’ll gain the tools to defend your practice and ensure compliance in this rapidly evolving landscape.
Dr. Ronald Hirsch dives into the basics of Medicare for clinicians to be successful as utilization review professionals. He’ll break down what Medicare does and doesn’t pay for, what services it provides and how hospitals get paid for providing those services – including both inpatient and outpatient. Learn how claims are prepared and how much patients must pay for their care. By attending our webcast, you will gain a new understanding of these issues and be better equipped to talk to patients, to their medical staff, and to their administrative team.
Copyright © 2025 ICD10monitor. Powered by MedLearn Media.
Celebrate Lab Week with MedLearn! Sign up to win one year of our Laboratory All Access Pass! Click here to learn more →
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
